Piergiorgio Donati

Outlook Microsoft Office 365 Zendesk Mobile Friendly reCAPTCHA YouTube New Relic WordPress.org Google Tag Manager Google Analytics Bootstrap Framework Remote AI

therapeutics alzheimers disease neuroorphan diseases parkinsons disease diagnostics neurodegenerative diseases down syndrome misfolded proteins biotechnology: pharmaceutical preparations health care biotechnology research precision medicine alzheimer's disease parkinson's disease active immunotherapy biotherapeutics diagnostic agents tau protein a-synuclein small molecule drugs clinical trials proteinopathies biopharmaceutical morphomer platform supraantigen therapeutic focus patient monitoring early intervention pathological proteins disease prevention biomarker application phd clinical stage pipeline therapeutic candidates diagnostic candidates clinical development cns-targeting neuron preservation immune response biogen anti-abeta fda fast track designation tau aggregation clinical pipeline partner collaboration molecular imaging cns diseases tau-pet therapeutic modalities protein aggregation neuroinflammation tdp-43 novel targets orphan indications biological markers patient-centric approach collaborative partnerships immunogenicity diagnostic validation longitudinal studies clinical-stage biopharmaceutical active immunotherapies proprietary technology platforms morphomer biomarker-driven therapies therapeutic development patient-specific diagnostics strategic partnerships janssen pharmaceuticals takeda eli lilly innovative therapies healthcare providers researchers pharmaceutical companies aging population protein misfolding market expansion transformative therapies scientific discovery collaboration integrity excellence global presence switzerland usa financial health competitive analysis drug discovery patient demographics healthcare professionals research institutions commercialization licensing agreements innovative biologics manufacturing capabilities health wellness & fitness hospital & health care